Indivior Pharmaceuticals Inc

NASDAQ:INDV

Drug Manufacturers - Specialty & Generic

Healthcare
$36.28 +0.69%

+$0.26 today

Market cap
$4.53B
Beta
1.17
P/E (TTM)
19.1
EPS (TTM)
$2.00
52W Low $13.45High $41.00

Volume 3.65M

Average 2.08M

INDV Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Indivior Pharmaceuticals IncNASDAQ: INDV

Change in Working Capital · Q2 FY2026 · quarter ended Jun 2026

Change in working capital dips below year-ago levels

Q2 FY2026 change in working capital of $64M fell 47.1% year over year, behind the +2052.2% change in trailing-twelve-month change in working capital.

Context

  • Change in working capital amounted to 20.7% of revenue in FY2025, up 16.9 pp from a year earlier.
  • Change in working capital increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -47.1% toward the trailing-twelve-month pace of +2052.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$64M+139.3% QoQ
Last fiscal yearDec 2025
-$257M+458.7% YoY
LTMJun 2026
-$495M+2052.2% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-47.1%——
1 year+458.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(257M) USD
Year-over-year change
-458.7%

Change in Working Capital vs competitors

How INDV compares with its peers on the latest reported figures

  • INDV's LTM Jun 2026 change in working capital of $495M is the largest of the 4 companies compared; the peer median is $4.39M.
  • Its year-over-year change of +2052.2% is the highest of 4, against a peer median of -93.3%.
  • Change in working capital amounts to 37.2% of revenue for INDV, versus a peer median of 5.2%.
INDV Competitors Peer median
Change in Working Capital for INDV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INDVIndivior Pharmaceuticals IncLTM Jun 2026$495M +2052.2%—37.2%
ALKSAlkermes plcLTM Sep 2026$91.41M +164.0%+110.8%5.2%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$81.59M -758.8%+45.8%9.8%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$4.39M -93.3%—0.6%
Peer median (excluding INDV) $4.39M-93.3%+78.3%5.2%

Competitors are the stored peer set for INDV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income213M(44M)(126M)7M210M
Depreciation & Amortization22M16M15M28M20M
Deferred Income Tax00(64M)7M(46M)
Stock-Based Compensation11M16M21M24M26M
Change in Working Capital173M118M(297M)(46M)(257M)
Accounts Receivables(25M)(21M)(33M)(1M)3M
Inventory(3M)(30M)(6M)(43M)18M
Accounts Payables00000
Other Working Capital201M169M(258M)(2M)(278M)
Other Non-Cash Items(66M)(110M)151M16M20M
Operating Cash Flow353M(4M)(300M)36M(27M)
Capital Expenditures(34M)(5M)(53M)(31M)(67M)
Acquisitions (Net)00(129M)00
Purchases of Investments0(245M)(45M)(17M)(20M)
Sales of Investments027M129M117M20M
Other Investing Activities(10M)1M(42M)(2M)0
Investing Cash Flow(14M)(222M)(95M)69M(66M)
Debt Repayment14M(3M)(12M)92M(17M)
Common Stock Issued1M(8M)(19M)(19M)(3M)
Common Stock Repurchased(101M)(90M)(33M)(173M)(11M)
Dividends Paid00000
Other Financing Activities(8M)00(2M)1M
Financing Cash Flow(94M)(101M)(64M)(102M)(30M)
Effect of Forex Changes(1M)(1M)1M0(1M)
Net Change in Cash244M(328M)(458M)3M(124M)
Free Cash Flow319M(9M)(353M)5M(94M)

Indivior Pharmaceuticals Inc

NASDAQ:INDV

Intrinsic Alpha fair value

Locked

Current Price

$36.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.